Pharmacy Review for Life Insurance Claims
Reduce medication risk and strengthen claim assessment through specialist pharmacy review
Published: 3 April 2026 | Updated: 3 April 2026
Why Life Insurance Claims Need Medication Review
Life insurance claims often hinge on understanding your claimant's medical stability and functional capacity. Medication management is central to both. A claimant's complex medication regime may indicate ongoing instability or poorly managed chronic disease. Conversely, appropriate medications properly dosed and coordinated may support stability and actual capacity better than raw diagnosis suggests.
Your claims assessors work from medical records and diagnosis codes. They miss the pharmacy-level reality: whether medications are working, whether they're appropriate for the claimant's functional status, whether dosing is evidence-based, and whether the medication regime itself is creating risk. You need specialist pharmacy review to fill this gap. IMM's pharmacist-led assessments provide objective, evidence-based medication analysis that informs your life claims decision-making.
Life insurance reality: Medication complexity is often a red flag for instability or poor disease management. But appropriate medication management is also the foundation of stability. Pharmacy review tells you which is true for your claimant.
What IMM Reviews in Life Insurance Claims
Medication Appropriateness and Indication Justification
We examine each medication and verify clear clinical justification. We assess whether medications align with the claimant's documented diagnoses and whether the regime as a whole makes clinical sense. We identify duplication, inappropriate combinations, or medications that suggest undisclosed or inadequately managed conditions.
Dosing and Evidence-Based Practice
Doses vary widely. Some claimants are under-dosed, meaning their condition is poorly managed. Others are over-dosed, suggesting either physician caution or possible medication abuse patterns. We benchmark doses against evidence-based guidelines and best practice, identifying outliers that suggest clinical concerns.
Drug Interactions and Safety Risk
Multi-medication regimes create interaction risks. We screen for pharmacokinetic and pharmacodynamic interactions that may worsen disease stability, create new medical problems, or suggest medication management issues. Interaction complexity can be a marker of assessment risk.
Medication Adherence and Management Risk
Medication regime complexity correlates with adherence risk. We assess whether the claimant's regime is realistic to manage and whether medication management itself creates a stability risk. We identify patterns that suggest medication non-compliance or potential abuse.
Chronic Disease Control and Stability Assessment
Appropriate medication therapy should translate to disease control and functional stability. We assess alignment between medication regime and documented clinical outcomes. Disconnect between medications and clinical stability is a red flag.
How Pharmacy Review Informs Life Insurance Decision-Making
Step 1: Claim Assessment
At claim lodgement, if the claimant's medical summary includes complex medications, refer for pharmacy review to establish baseline medication appropriateness and identify any red flags in medication management.
Step 2: Evidence Gathering
During investigation, use IMM's review to identify whether medication patterns support or contradict the claimant's account of functional capacity and disease stability. Medication analysis often reveals information not captured in traditional medical records.
Step 3: Decision Support
During assessment, use IMM's findings to support your decision on medical stability, functional capacity, and claim risk. Pharmacy review provides evidence-based medication context that strengthens your assessment.
Real-World Scenario: Life Insurance Claim
Situation: A 48-year-old claimant lodges a total permanent disability claim citing ongoing back pain and depression. Medical records show treatment for chronic pain, depression, and anxiety. Current medications: oxycodone, pregabalin, duloxetine, alprazolam, sertraline, and zopiclone. Claimant claims inability to work due to pain and cognitive impairment. Claims assessor questions whether disability claim is justified.
IMM Review Findings: Duloxetine and sertraline both treat depression through serotonin pathways; combination is excessive. Pregabalin and oxycodone both address pain; dosing of both suggests inadequate pain control despite combination therapy, indicating either under-treatment or pain perception greater than expected. Alprazolam and zopiclone both create sedation; combination is contraindicated. Alprazolam indicates ongoing high anxiety despite duloxetine and sertraline therapy. Medication regime suggests poorly controlled mental health alongside pain, supporting (not contradicting) the claimant's stated functional limitations.
Outcome: IMM's review supports the claims assessor's decision that medication regime reflects genuine medical complexity and poor stability. Claimant's account of functional limitation aligns with medication profile. Claim approved with confidence in the assessment basis.
Medication Patterns That Suggest Claim Risk
IMM's pharmacy reviews identify medication patterns that should trigger caution in your assessment:
- Multiple medications with overlapping mechanisms (suggests poor disease control or physician uncertainty)
- Doses significantly higher or lower than evidence-based recommendations (suggests atypical disease pattern or management issues)
- Contraindicated drug combinations (suggests inadequate prescriber awareness or medication management breakdown)
- Extended use of medications typically prescribed short-term (benzodiazepines beyond 4 weeks; suggests dependency risk)
- Frequent medication changes without documented indication (suggests instability or medication-seeking behaviour)
- Claimant's functional capacity inconsistent with medication-supported disease control (red flag for credibility assessment)
Pharmacy Review Across Life Insurance Portfolio
Mental health claims: Medication regime complexity (multiple antidepressants, antipsychotics, anxiolytics) is common in depression and bipolar disorder claims. Pharmacy review assesses medication appropriateness and identifies whether regime suggests poor treatment response (red flag) or appropriate management of complex condition.
Chronic pain claims: Opioid, gabapentinoid, and SNRI combinations are common. Pharmacy review benchmarks doses, assesses appropriateness, and identifies whether regime supports claimed functional limitations or suggests other risk patterns (medication-seeking, overtreatment).
Neurological claims: Epilepsy, Parkinson's, and multiple sclerosis claims often involve complex medication regimes. Pharmacy review assesses dose appropriateness, drug interactions, and alignment between medications and claimed functional status.
Cardiovascular and metabolic claims: Multiple medications are standard. Pharmacy review identifies whether regime addresses all identified risk factors and whether dosing aligns with evidence and claimant risk profile.
| Condition Category | Pharmacy Review Focus | Red Flags |
|---|---|---|
| Mental health | Medication appropriateness for disease control and stability | Multiple antidepressants; high doses of anxiolytics; recent changes |
| Chronic pain | Evidence-based dosing; combination appropriateness; functional alignment | High-dose opioids; gabapentinoid combinations; frequent increases |
| Neurological | Disease-specific medication efficacy and interactions | Dose escalations; inadequate disease control despite treatment; drug interactions |
Strengthen your life insurance claims assessment through pharmacy review.
IMM's specialist pharmacist reviews provide objective medication analysis that informs your claims decision-making. Assess medication appropriateness, identify red flags in medication patterns, and support your assessment with evidence-based pharmacy expertise. Available across Australia and New Zealand.
Request a Medication Review
